E-PaperSamrat Pharmachem Q4 results : profit at ₹1.4Cr, Revenue increased by 19.77% YoY
Samrat Pharmachem Q4 results : Revenue increased by 19.77% YoY & profit at ₹1.4Cr
Samrat Pharmachem Q4 Results Live : Samrat Pharmachem declared their Q4 results on 30 May, 2024. The topline increased by 19.77% & the profitcame at ₹1.4cr. It is noteworthy that Samrat Pharmachem had declared loss of ₹0.74cr in previous fiscal year same period. As compared to the previous quarter the revenue grew by 34.06%.
The Selling, general & administrative expenses rose by 16.3% q-o-q & increased by 12.88% Y-o-Y.
The operating income was up by 2810.2% q-o-q & increased by 249.19% Y-o-Y.
The EPS is ₹4.52 for Q4 which increased by 287.52% Y-o-Y.
Samrat Pharmachem has delivered -3.86% return in the last 1 week, -1.54% return in last 6 months and 2.7% YTD return.
Currently the Samrat Pharmachem has a market cap of ₹110.49 Cr and 52wk high/low of ₹533.6 & ₹320 respectively.
Samrat Pharmachem Financials
| Period | Q4 | Q3 | Q-o-Q Growth | Q4 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 82.68 | 61.67 | +34.06% | 69.03 | +19.77% |
| Selling/ General/ Admin Expenses Total | 0.66 | 0.56 | +16.3% | 0.58 | +12.88% |
| Depreciation/ Amortization | 0.16 | 0.16 | -1.3% | 0.16 | -2.74% |
| Total Operating Expense | 81.49 | 61.72 | +32.03% | 69.83 | +16.69% |
| Operating Income | 1.2 | -0.04 | +2810.2% | -0.8 | +249.19% |
| Net Income Before Taxes | 1.39 | 0.14 | +885.32% | -0.79 | +275.66% |
| Net Income | 1.4 | 0.34 | +305.14% | -0.74 | +287.31% |
| Diluted Normalized EPS | 4.52 | 1.11 | +307.21% | -2.41 | +287.52% |
- Top Gainers
- Top Losers
- 52 Week High
